170 related articles for article (PubMed ID: 21625938)
1. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study.
Magraner MJ; Coret F; Navarré A; Boscá I; Simó M; Escutia M; Bernad A; Navarro L; Casanova B
J Neurol; 2011 Oct; 258(10):1805-11. PubMed ID: 21625938
[TBL] [Abstract][Full Text] [Related]
2. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.
Havla J; Gerdes LA; Meinl I; Krumbholz M; Faber H; Weber F; Pellkofer HL; Hohlfeld R; Kümpfel T
J Neurol; 2011 Sep; 258(9):1665-9. PubMed ID: 21431380
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation.
Mustonen T; Rauma I; Hartikainen P; Krüger J; Niiranen M; Selander T; Simula S; Remes AM; Kuusisto H
Mult Scler Relat Disord; 2020 Feb; 38():101498. PubMed ID: 31864192
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
5. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Gobbi C; Meier DS; Cotton F; Sintzel M; Leppert D; Guttmann CR; Zecca C
BMC Neurol; 2013 Aug; 13():101. PubMed ID: 23915113
[TBL] [Abstract][Full Text] [Related]
7. Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.
Villaverde-González R; Gracia Gil J; Pérez Sempere A; Millán Pascual J; Marín Marín J; Carcelén Gadea M; Gabaldón Torres L; Moreno Escribano A; Candeliere Merlicco A
Eur Neurol; 2017; 77(3-4):130-136. PubMed ID: 28052269
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
9. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
11. Treatment options to reduce disease activity after natalizumab: paradoxical effects of corticosteroids.
Rossi S; Motta C; Studer V; Boffa L; De Chiara V; Castelli M; Barbieri F; Buttari F; Monteleone F; Germani G; Macchiarulo G; Weiss S; Centonze D
CNS Neurosci Ther; 2014 Aug; 20(8):748-53. PubMed ID: 24837039
[TBL] [Abstract][Full Text] [Related]
12. Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses.
Rovaris M; Codella M; Moiola L; Ghezzi A; Zaffaroni M; Mancardi G; Capello E; Sardanelli F; Comi G; Filippi M
Neurology; 2002 Nov; 59(9):1429-32. PubMed ID: 12427898
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Harrison DM; Gladstone DE; Hammond E; Cheng J; Jones RJ; Brodsky RA; Kerr D; McArthur JC; Kaplin A
Mult Scler; 2012 Feb; 18(2):202-9. PubMed ID: 21865410
[TBL] [Abstract][Full Text] [Related]
14. Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS?
Van Obberghen EK; Cohen M; Rocher F; Lebrun-Frenay C
Rev Neurol (Paris); 2017 Apr; 173(4):222-224. PubMed ID: 28372806
[TBL] [Abstract][Full Text] [Related]
15. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Gueguen A; Roux P; Deschamps R; Moulignier A; Bensa C; Savatovsky J; Heran F; Gout O
J Neurol Neurosurg Psychiatry; 2014 Sep; 85(9):1038-40. PubMed ID: 24876183
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
[TBL] [Abstract][Full Text] [Related]
17. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
Ozakbas S; Cinar BP; Kosehasanoğullari G; Kahraman T; Oz D; Kursun BB
Clin Neurol Neurosurg; 2017 Sep; 160():69-72. PubMed ID: 28689102
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
Hemmer B; Wiendl H; Roth K; Wessels H; Höfler J; Hornuss C; Liedert B; Selmaj K
JAMA Neurol; 2023 Mar; 80(3):298-307. PubMed ID: 36689214
[TBL] [Abstract][Full Text] [Related]
19. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
20. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N; Filippi M; Hawkins C;
J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
